News & Updates

Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.

Individuals who are exposed to asbestos are at higher risk of lung cancer despite modest exposure to tobacco, reveals a recent study.

Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.

In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.